POLYSACCHARIDE CONJUGATE VACCINE RESPONSES IN BONE-MARROW TRANSPLANT PATIENTS

Bone marrow transplant patients have impaired responses to pure polysaccharide (PS) vaccines and are at an increased risk for disease caused by PS encapsulated pathogens such as Haemophilus influenzae type B (HIB) and Streptococcus pneumoniae. We immunized 35 BMT patients (21 allogeneic and 14 autologous) ages 2-45 years with pure PS pneumococcal (Pnu-imune 23), HIB-conjugate (HibTITER), and tetanus toroid vaccines. Patients were assigned to receive vaccines at either 12 and 24 months after transplantation or at 24 months only. Only 19% of all enrolled patients developed protective antibody concentrations (greater than or equal to 0.300 mu g antibody nitrogen/ml) to the 6 pneumococcal serotypes measured after the 24-month immunization. Poor response to pneumococcal vaccine was not different for the 2 study groups and was similar to previous studies. In contrast, HIB-coqjugate vaccine elicited protective concentrations of antibody (greater than or equal to 1.0 mu g/ml) in 56% of patients after 1 dose and in 80% after 2 doses. The group that received 2 doses of HIB-conjugate vaccine had a significantly higher geometric mean antibody concentration of 14.5 mu g/ml as compared with 1.43 mu g/ml for those receiving only 1 dose (P=0.012). Responses to tetanus toroid vaccine were similar to HIB-conjugate vaccine, with a booster response documented after the second dose. In summary 2 doses of HIB-coqjugate vaccine given at 12 and 24 months after transplantation produced protective antibody concentrations in 80% of patients. While the response to pure PS pneumococcal vaccine was poor, the results with HIB-coqjugate vaccine suggest that future pneumococcal conjugate vaccines may also benefit BMT patients.